WO1997032870A1 - Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique - Google Patents
Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique Download PDFInfo
- Publication number
- WO1997032870A1 WO1997032870A1 PCT/FR1997/000383 FR9700383W WO9732870A1 WO 1997032870 A1 WO1997032870 A1 WO 1997032870A1 FR 9700383 W FR9700383 W FR 9700383W WO 9732870 A1 WO9732870 A1 WO 9732870A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- benzofuran
- compounds
- compound
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the subject of the present invention is derivatives of
- - A represents either a hydrogen atom or a hydroxyl group
- - B represents either a hydrogen atom or a C 1-8 alkyl, C 1-8 alkenyl, C 1-8 fluoroalkyl or C 1-8 group
- R 1 , R 2 , R 5 identical or different, each represent a hydrogen atom, a halogen such as chlorine, bromine or fluorine, a C 1-8 alkyl, C 1-8 alkenyl group, C 3-8
- cycloalkyl C 3-8 cycloalkenyl, C 6 , C 10 or C 14 aryl, C 1-6 alkoxycarbonyl, C 1-6 hydroxyalkyl, C 1-6 alkoxyalkyl, C 1-6 alkoxy, C 1-8 fluoroalkyl or C 1-8 perfluoroalkyl,
- R 1 and R 2 together form a C 3-B cycloalkyl, C 3-8 cycloalkenyl ring, or a C 6 , C 10 or C 14 aryl, with the exception of the compounds for which R 1 and R 2 are simultaneously
- R 3 and R 4 identical or different, represent either a hydrogen atom or a C 1-8 alkyl, C 1-8 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl group,
- R 3 and R 4 together form a C 2-6 cycloalkyl ring, C 3-6 cycloalkenyl, such as for example a piperidyl,
- azetidinyl or pyrrolidyl azetidinyl or pyrrolidyl.
- the preferred compounds according to the invention are those comprising radicals having the following meanings:
- R 1 and R 2 each represent a C 1 -C 4 alkyl group, more preferably methyl, ethyl or i-propyl, or a group
- R 1 and R 2 together form a C 3 -C 6 cycloalkyl group
- R 3 and R 4 each represent a C 1 -C 4 alkyl group, more preferably a methyl, ethyl or
- R 5 represents a hydrogen atom
- the compounds of the invention can be used as a medicament as contracting agents for smooth muscles, and more particularly in the treatment of urinary incontinence, or as veno-constrictors, and more
- the patent FR 1 532 210 describes a very large family of heterocyclic compounds of formula W,
- benzofuran These compounds are described as agents blocking the beta-adrenergic effect and are used in the curative or prophylactic treatment of affections
- the compounds of general formula (I) contain one or
- the pharmaceutically acceptable salts of the compounds of formula (I) according to the invention can be either salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid, or salts organic acids such as acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, methanesulfonic acid or fumaric acid.
- mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid
- organic acids such as acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, methanesulfonic acid or fumaric acid.
- hydrochloric acid salts are preferred.
- the compounds derived from 2-aminoethyl-benzofuran of formula (I) according to the invention can be prepared according to different methods. These processes are described below. 1.
- the compounds of formula (I), in particular those for which A represents a hydroxyl group, can be prepared according to the process described in the appendix.
- an aldehyde of formula II is reacted with an aminoalkyl stannate derivative of formula III.
- the meanings of R 1 , R 2 , R 3 , R 4 , R 5 and B of the compounds of formula II and III are those indicated in formula I.
- This reaction can be carried out in an organic solvent such as tetrahydrofuran, in presence of n-butyl lithium.
- the compounds of formula III can be prepared by a person skilled in the art according to the method described by Katrizky, A.R .; Chang,
- the formylation reaction can be carried out in an organic solvent such as tetrahydrofuran, N, N-d ⁇ méthylforrrtam ⁇ de or a mixture of these solvents.
- the compounds of formula IV can themselves be prepared from ⁇ -phenoxyketones of formula V which are made: react with an acid, preferably a mineral acid, such as polyphosphoric acid or, advantageously sulfuric acid.
- an acid preferably a mineral acid, such as polyphosphoric acid or, advantageously sulfuric acid.
- R 1 , R 2 and R 5 for the compounds of formulas IV and V are those indicated in formula I.
- the compounds of formula V can be obtained directly from the corresponding phenols of formula VI which are reacted with an ⁇ -haloketone of formula VII. This reaction can be carried out in an organic solvent, such as
- N, N-d ⁇ méthylformam ⁇ de in the presence of potassium carbonate and an iodide such as potassium iodide.
- the ⁇ -haloketone moiety is usually an ⁇ -chloroketone.
- R 1 , R 2 and R 5 for the compounds of formulas VI and VII, are those indicated in formula I.
- the compounds of formula V can also be prepared by reaction of a compound of formula VI as defined above, with an ⁇ -haloester of formula VIII, where R 1 has the meaning indicated in formula I.
- This reaction can be carried out in an organic solvent such as N, N-d ⁇ méthylformamide, in the presence of potassium carbonate and an iodide such as potassium iodide.
- an organic solvent such as N, N-d ⁇ méthylformamide
- the product of this reaction is then saponified with a base such as sodium hydroxide, to form a compound of formula IX.
- the latter is then transformed into its acid chloride or its Weinreb amide, by reaction with, for example, thionyl chloride (SO 2 Cl 2 ) or a mixture of SO 2 Cl 2 / NHCH 3 OCH 3 , under the conditions described by Nahm and Weinreb, Tet. Lett., 22, 3815, 1981.
- Said compound of formula V can then be prepared by reaction between the acid chloride of compound IX or the Weinreb amide thereof, with an organometallic of formula X, for which R 2 is as defined in formula (I) and X represents a halogen atom.
- organometallic is preferably an organomagnesium.
- a compound of formula VI as defined above is reacted with propargyl bromide.
- This reaction can be carried out in an organic solvent such as N, N-dimethylformamide, in the presence of potassium carbonate and an iodide such as potassium iodide.
- 0.2 to 2 moles of propargyl bromide are reacted for one mole of compound of formula VI.
- the phenoxypropargyl derivative of formula XI thus obtained is then reacted with diethylaniline in the presence of cesium fluoride, this under the conditions described by Ishi, H.; Ishihawa, T.; Takeda, S.; Veki, S .; Suzuki, M., Chem. Pharm. Bull., 40, 1992, 1148. 2.
- the compounds of formula (I) according to the invention, for which A is a hydroxyl group can also be prepared according to the following reaction scheme (2):
- the hydroxyl group twinned with group B of the diol thus obtained can then be optionally activated selectively, in a manner known to those skilled in the art so as to obtain the compound of formula XV.
- W represents a hydroxyl group or, when the hydroxyl group has been activated, W represents a nucleofuge group, such as a cosyl group, a mesyl group or a bromine atom.
- the ethenyl benzofuran derivative of formula XIV can itself be prepared from a benzofuran of formula IV as defined above, by palladic coupling of Stille, under the conditions defined by Me Kean, D.R.; Panneilo, G.;
- the ethenyl benzofuran derivative of formula XIV can be prepared from an aldehyde derivative of formula II, by a Wittig reaction under conditions conventional for those skilled in the art.
- the compound of formula (I) is prepared by reacting an oxirane derivative of formula XVI with an amme NHR 3 R 4 .
- the meanings of R 1 , R 2 , R 3 , R 4 , R 5 and B of the oxirane derivative of formula XVI and of said amme are those indicated above in formula I.
- the oxirane derivative of formula XVI can be prepared according to one of the following processes:
- the ketone is halogenated in the ⁇ position, reduced to halohydnne, then treated with a base and converted to oxirane XVI.
- the compound of formula XIX obtained can then be activated, for example by means of mesyl chloride (MsCl), and it is then reacted with an amme NHR 3 R 4 , as defined above.
- MsCl mesyl chloride
- an amme NHR 3 R 4 as defined above.
- 0.01 to 1 mole of compound of formula XIX is used for one mole of said core.
- the compounds of formula (I) according to the invention for which A is a hydrogen atom, can also be prepared by dehydroxylation of a corresponding compound of formula (I), where A is a hydroxyl group.
- the dehydroxylation reaction can be carried out, in a manner known to those skilled in the art, by reaction with triethylsilane and trifluroacetic acid.
- Example 1 ethyl 2- (2-bromo-phenoxy) -pentanoate:
- Eb point 100 ° C (0.8 mb; 80 Pa).
- step (4) To the 2,3-dimethyl-7- (2-diethylammo-1-hydroxyethyl) -benzofuran obtained in step (4), add 1/2 equivalent of oxalic acid in 2M solution in methanol and the salt is concentrated. under vacuum, recrystallized from ethyl acetate and then dried in a desiccator under vacuum over phosphoric anhydride.
- This compound is obtained according to the process described in step (1) of Example 1 for the preparation of 3- (2-bromo-phenoxy) -2- butanone, from 3-hydroxy-phenol.
- This compound is obtained by the process described in step (3) of Example 1, using as starting material 2-methyl-7-bromo-benzofuran.
- This compound is obtained by the process described in step (4) of Example 1, using as starting material 2-methyl-7-formyl-benzofuran.
- Example 15 Asymmetric synthesis of (+) - 2,3-dimethyl-7- (2-diethylammo-1 (S) -hydroxyethyl) -benzofurane. (1) 2,3-dimethyl-7-ethenyl-benzofuran
- reaction mixture is allowed to return to ambient temperature, then 500 ml of ethyl acetate and 500 ml of sodium hydroxide are added.
- the organic phase is washed with brine, dried over magnesium sulfate and concentrated.
- the residue is distilled under a vacuum of 0.03 mm Hg.
- the fraction passing between 60 and 78 ° C is collected which is then purified by chromatography on a silica column (elution solvent 1% ethyl acetate in cyclohexane). 13.5 g of 2,3-dimethyl-7-etheny-benzofuran are obtained in the form of a colorless oil.
- AD mix ⁇ complex based on K 2 OsO 2 (OH) 4 , Fe (CN) 6 and, as ligand, dihydroquinmel, 4-phthalazmediyl diether
- 358 ml of water 358 ml of tert-butanol.
- 12.3 g (71.5 mmol) of 2,3-dimethyl-7-ethenyl-benzofuran are added and the reaction mixture is stirred at 0 ° C for 6 h.
- the enantiomeric excess is 98.5%.
- An excess of an ethanol solution saturated with anhydrous hydrochloric acid is added and the salt is concentrated under vacuum, recrystallized from ethyl acetate and then dried in a desiccator under vacuum over phosphoric anhydride.
- Steps 1 to 4 of Example 15 were reproduced, using however in step 2, AD mix 3 (complex based on K 2 OsO 2 (OH) 4 , Fe (CN) 6 and , as a ligand, of
- step (2) (-) - 2,3-dimethyl-7- (2-hydroxy-1 (R) - hydroxyethyl) -benzofuran, in the form of a colorless oil.
- step (3) (-) - 2,3-dimethyl-7- (2-para-toluenesulfonate-
- the solution is stirred at reflux, under a stream of nitrogen, for 1 h 30 min, regularly adding a small amount of acetonitrile: water mixture (84:16) to replace the distilled solvent.
- the mixture is then concentrated in vacuo and the residue is purified by chromatographic column (elution solvent dichoromethane: methanol 90:10) then dried in a desiccator under vacuum over phosphoric anhydride.
- This compound is prepared from 2-bromo-phenol according to the procedure of Boehme, W., R., Organic Syntician, Coll. Flight. IV, 590.
- This compound is obtained according to the method described in Example 6 for the preparation of 2,3-methyl-7-ethenyl-benzofuran, using 2-ethyloxycarbonyl-3-methyl-7-bromo-benzofuran as starting material.
- - "-" represents a compound in free form
- - nC 3 H 7 represents a linear propyl group
- - iC 3 H 7 represents a 1 -propyl group
- - nC 6 H 13 represents a linear cyclohexyl group.
- hydrochloric salts described in the Table were prepared as follows:
- the compounds of the invention were subjected to biological tests intended to demonstrate their selective smooth muscle contracting activity.
- the in vitro activity of the compounds of the invention has been studied on the urethral and arterial smooth muscles.
- the contractile effect of each compound is evaluated by calculating pD 2 (negative logarithm of the agonist concentration which induces 50% of the maximum contraction) as well as by the Maximum effect representing the percentage of the maximum contraction obtained with the phenylephrine (% E max ).
- Wistar rats are anesthetized and demedulated (according to the technique described by Gillespie, MacLaren A. and Polock D., A method of stimulatmg different segments of the autonomy outflow from the spinal column to various organs m the pithed cat and rat Br J. Pharmacol., 1970, 40: 257-267).
- the catheters are introduced through the aorta and a jugular vein. Another catheter is introduced into the urethra through an incision made in the bladder.
- the test compounds are administered in increasing doses by intravenous infusion. venous.
- the results are expressed in doses ( ⁇ g / kg) necessary to increase the urethral pressure by 10 cm of water (PU 10 ) or the blood pressure by 10 mm Hg (PA 10 ) or 50 mm Hg (PA 50 ) .
- the compounds of the invention thus tested, made it possible to obtain: - a PU 10 with doses less than 100 ⁇ g / kg, usually between 20 and 50 ⁇ g / kg, a PA 10 with higher doses at 110 ⁇ g / kg, usually between 130 and 250 ⁇ g / kg,
- test compounds are administered 5 to 15 days after the operation, by intravenous (i.v.) or oral (p.o.) administration.
- the compounds are administered i.v. in 5 minutes, in a single dose (100 ⁇ g / kg).
- the compounds are administered orally by gavage at a dose of 3 mg / kg.
- the results obtained are expressed as a percentage of premedication values at 5 minutes after dosing.
- the compounds of the invention thus tested allowed an increase in the PU greater than 70%, usually between 90 and 25%.
- the increase in BP was always less than 10%, usually it was 0%.
- the compounds according to the invention can be used as a medicament, in particular as a contracting agent for smooth muscles, and more particularly still, in the treatment of urinary incontinence, in particular stress urinary incontinence.
- the compounds according to the invention exhibit good efficacy and, usually, less side effects than the drugs conventionally used for such treatment, in particular as regards the side effects affecting the arteries.
- the compounds of the invention were subjected to biological tests intended to demonstrate their venoconstrictor activity.
- the in vitro activity of the compounds of the invention was studied on the saphenous veins of Yucatan micro-pigs.
- the tissue is cut in a helix and mounted in a tank with isolated organs in a modified Krebs solution oxygenated with a mixture of 95% O 2 and 5% CO 2 maintained at 37 ° C.
- the vessel is connected to an isometric sensor at a basal voltage of 1 g and connected to a polygraph allowing the recording of blood pressure variations.
- the viability of each preparation is tested by pre-stimulation with noradrenaline 3 ⁇ M.
- the compound to be studied is introduced and its concentration curve - response constructed cumulatively until a maximum response is obtained.
- the contractile effect of each compound is evaluated by calculation of the EC 50 (concentration producing 50% of the maximum response).
- the compounds of the invention have made it possible to obtain a venoconstrictor activity with an EC 50 value usually between 1 ⁇ M and 100 ⁇ M.
- the compounds of the invention can be used in the treatment of venous insufficiency and venous ulcer.
- the compounds according to the invention can also be used for the treatment of migraine, gastrointestinal disorders and as a vasoconstrictor of the nasal mucosa.
- the compounds according to the invention can be presented in different pharmaceutical forms suitable for oral administration and for topical application, if necessary in combination with at least one pharmaceutical excipient.
- suitable pharmaceutical forms are for example tablets, capsules, dragees, capsules, oral or injectable solutions, syrups, suppositories. These pharmaceutical forms can be dosed to allow a daily dose of 0.1 ⁇ g / kg to 50 mg / kg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20301/97A AU2030197A (en) | 1996-03-08 | 1997-03-05 | 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof |
JP9531521A JP2000506157A (ja) | 1996-03-08 | 1997-03-05 | (2―アミノエチル)ベンゾフラン誘導体、その製造およびその治療的使用 |
EP97908303A EP0888324A1 (fr) | 1996-03-08 | 1997-03-05 | Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique |
US09/125,947 US6063810A (en) | 1996-03-08 | 1997-03-05 | 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9602938A FR2745815B1 (fr) | 1996-03-08 | 1996-03-08 | Derives de benzofurane, leur preparations et compositions pharmaceutiques les comprenant |
FR96/02938 | 1996-03-08 | ||
FR96/10829 | 1996-09-05 | ||
FR9610829A FR2752735B1 (fr) | 1996-09-05 | 1996-09-05 | Utilisation de derives de benzofurane pour obtenir un medicament destine au traitement de l'insuffisance veineuse et de l'ulcere veineux |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997032870A1 true WO1997032870A1 (fr) | 1997-09-12 |
Family
ID=26232574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/000383 WO1997032870A1 (fr) | 1996-03-08 | 1997-03-05 | Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique |
Country Status (5)
Country | Link |
---|---|
US (1) | US6063810A (fr) |
EP (1) | EP0888324A1 (fr) |
JP (1) | JP2000506157A (fr) |
AU (1) | AU2030197A (fr) |
WO (1) | WO1997032870A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2781799A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Derives de benzofurane et de benzothiophene, leurs preparations et applications en therapeutique |
FR2781800A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Derives de 2-aminoethyl-benzofurane et de 2-aminoethyl-benzothiophene, leurs preparations et leurs applications en therapeutique |
FR2783247A1 (fr) * | 1998-09-10 | 2000-03-17 | Synthelabo | Derives de 2-aminoethyl-quinoleine, leur preparation et leur application en therapeutique |
FR2785903A1 (fr) * | 1998-11-17 | 2000-05-19 | Synthelabo | Derives de 1-aminoethylquinoleine, leur preparation et leur application en therapeutique |
WO2001038310A1 (fr) * | 1999-11-25 | 2001-05-31 | Sanofi-Synthelabo | Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique |
WO2001044197A2 (fr) * | 1999-12-17 | 2001-06-21 | Sanofi-Synthelabo | Derives de 2-phenyl-quinoleine et leur utilisation en tant qu'agent contractant des muscles lisses |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2565205A1 (fr) * | 2004-05-03 | 2005-11-24 | Janssen Pharmaceutica N.V. | Nouveaux derives d'indole agissant comme modulateurs de recepteurs androgenes selectifs (sarm) |
CN101120002A (zh) * | 2005-02-17 | 2008-02-06 | 惠氏公司 | 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物 |
CN103214413B (zh) * | 2013-03-22 | 2015-05-13 | 郑州泰基鸿诺药物科技有限公司 | 一种含杂环的三氟甲基酮化合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1532210A (fr) * | 1963-06-21 | 1968-07-12 | Ici Ltd | Composés hétérocycliques et leur procédé de préparation |
EP0270342A2 (fr) * | 1986-12-02 | 1988-06-08 | Tanabe Seiyaku Co., Ltd. | Dérivé du benzofurane (ou -thiophène) et son procédé de préparation |
EP0306226A2 (fr) * | 1987-09-04 | 1989-03-08 | Tanabe Seiyaku Co., Ltd. | Dérivés du benzofurane et procédés pour leur préparation |
WO1993012754A2 (fr) * | 1991-12-20 | 1993-07-08 | Abbott Laboratories | Amines tertiaires et secondaires utilises comme antagonistes alpha-2 et inhibiteurs de fixation de la serotonine |
EP0558245A1 (fr) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Composés hétérobicycliques comme antagonistes des récepteurs alpha-1 adrénergiques et 5HT1A |
EP0693475A1 (fr) * | 1994-07-23 | 1996-01-24 | Grünenthal GmbH | Dérivés propane 1-phényl-3-diméthylamino à activité pharmocologique |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474994A (en) * | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
DK26793D0 (da) * | 1993-03-10 | 1993-03-10 | Novo Nordisk As | Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling |
-
1997
- 1997-03-05 EP EP97908303A patent/EP0888324A1/fr not_active Ceased
- 1997-03-05 US US09/125,947 patent/US6063810A/en not_active Expired - Fee Related
- 1997-03-05 WO PCT/FR1997/000383 patent/WO1997032870A1/fr not_active Application Discontinuation
- 1997-03-05 JP JP9531521A patent/JP2000506157A/ja active Pending
- 1997-03-05 AU AU20301/97A patent/AU2030197A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1532210A (fr) * | 1963-06-21 | 1968-07-12 | Ici Ltd | Composés hétérocycliques et leur procédé de préparation |
EP0270342A2 (fr) * | 1986-12-02 | 1988-06-08 | Tanabe Seiyaku Co., Ltd. | Dérivé du benzofurane (ou -thiophène) et son procédé de préparation |
EP0306226A2 (fr) * | 1987-09-04 | 1989-03-08 | Tanabe Seiyaku Co., Ltd. | Dérivés du benzofurane et procédés pour leur préparation |
WO1993012754A2 (fr) * | 1991-12-20 | 1993-07-08 | Abbott Laboratories | Amines tertiaires et secondaires utilises comme antagonistes alpha-2 et inhibiteurs de fixation de la serotonine |
EP0558245A1 (fr) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Composés hétérobicycliques comme antagonistes des récepteurs alpha-1 adrénergiques et 5HT1A |
EP0693475A1 (fr) * | 1994-07-23 | 1996-01-24 | Grünenthal GmbH | Dérivés propane 1-phényl-3-diméthylamino à activité pharmocologique |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2781800A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Derives de 2-aminoethyl-benzofurane et de 2-aminoethyl-benzothiophene, leurs preparations et leurs applications en therapeutique |
FR2781799A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Derives de benzofurane et de benzothiophene, leurs preparations et applications en therapeutique |
FR2783247A1 (fr) * | 1998-09-10 | 2000-03-17 | Synthelabo | Derives de 2-aminoethyl-quinoleine, leur preparation et leur application en therapeutique |
WO2000015617A1 (fr) * | 1998-09-10 | 2000-03-23 | Sanofi-Synthelabo | Derives de 2-aminoethyl-quinoleine, leur preparation et leur application en therapeutique |
US6331549B1 (en) | 1998-11-17 | 2001-12-18 | Sanofi-Synthelabo | 1-aminoethylquinoline derivatives for treating urinary incontinence |
FR2785903A1 (fr) * | 1998-11-17 | 2000-05-19 | Synthelabo | Derives de 1-aminoethylquinoleine, leur preparation et leur application en therapeutique |
WO2000029379A1 (fr) * | 1998-11-17 | 2000-05-25 | Sanofi-Synthelabo | Derives de 1-aminoethylquinoleine pour le traitement de l'incontinence urinaire |
WO2001038310A1 (fr) * | 1999-11-25 | 2001-05-31 | Sanofi-Synthelabo | Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique |
FR2801589A1 (fr) * | 1999-11-25 | 2001-06-01 | Sanofi Synthelabo | Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique |
US6617336B1 (en) | 1999-11-25 | 2003-09-09 | Sanofi-Synthelabo | 2-arylquinoline derivatives, preparation and therapeutic use thereof |
WO2001044197A2 (fr) * | 1999-12-17 | 2001-06-21 | Sanofi-Synthelabo | Derives de 2-phenyl-quinoleine et leur utilisation en tant qu'agent contractant des muscles lisses |
FR2802532A1 (fr) * | 1999-12-17 | 2001-06-22 | Sanofi Synthelabo | Derives de 2-phenyl-quinoleine, leur preparation et leur application en therapeutique |
WO2001044197A3 (fr) * | 1999-12-17 | 2002-04-04 | Sanofi Synthelabo | Derives de 2-phenyl-quinoleine et leur utilisation en tant qu'agent contractant des muscles lisses |
Also Published As
Publication number | Publication date |
---|---|
EP0888324A1 (fr) | 1999-01-07 |
JP2000506157A (ja) | 2000-05-23 |
AU2030197A (en) | 1997-09-22 |
US6063810A (en) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000046219A1 (fr) | Derives de alpha-azacyclomethyl quinoleine pour le traitement de l'incontinence urinaire | |
FR2517302A1 (fr) | Esters et amides de 13 14-bisdehydroprostaglandines | |
EP0506532A1 (fr) | Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant | |
WO1997032870A1 (fr) | Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique | |
EP0418933A1 (fr) | Dérivés d'alcadiènes, leurs préparations, les médicaments les contenant et produits intermédiaires | |
EP0842148B1 (fr) | Derives de benzenesulfonamide, leur preparation et leurs applications en therapeutique | |
WO1998008834A1 (fr) | Derives de benzylamine, leur preparation et leur application en therapeutique | |
EP0500443B1 (fr) | Nouvelles phényléthanolamino- et phényléthanolaminométhyl-tétralines, procédé pour leur préparation, intermédiaires dans ce procédé et compositions pharmaceutiques les contenant | |
FR2752840A1 (fr) | Derives de benzothiophene, leur preparation et leur application en therapeutique | |
EP0573361B1 (fr) | Procédé de préparation d'esters de l'acide 2,2-diméthyl 3-((Z)-2-(alcoxycarbonyl)ethenyl cyclopropane carboxylique et intermédiaires | |
WO2000029379A1 (fr) | Derives de 1-aminoethylquinoleine pour le traitement de l'incontinence urinaire | |
FR2745815A1 (fr) | Derives de benzofurane, leur preparations et compositions pharmaceutiques les comprenant | |
EP1242381A2 (fr) | Derives de 2-phenyl-quinoleine et leur utilisation en tant qu'agent contractant des muscles lisses | |
EP1240146A1 (fr) | Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique | |
FR2619815A1 (fr) | Acides carboxyliques d'ethers cycliques a substituants gemines, leurs derives, et compositions a action therapeutique les contenant | |
CH648483A5 (fr) | Composition pharmaceutique contre l'arthrite rhumatoide. | |
FR2752735A1 (fr) | Utilisation de derives de benzofurane pour obtenir un medicament destine au traitement de l'insuffisance veineuse et de l'ulcere veineux | |
BE893917A (fr) | Derives n-imidazolyliques du 1,2,3,4-tetrahydro-naphtalene, de l'indane et du 1-chromane substitue en position 2 et procede pour les preparer | |
WO2000015617A1 (fr) | Derives de 2-aminoethyl-quinoleine, leur preparation et leur application en therapeutique | |
FR2741071A1 (fr) | Derives de 3-(benzofuran-5-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique | |
FR2758820A1 (fr) | Derives de alpha-azacyclomethyl-benzofurane, leur preparation et leur application en therapeutique | |
WO1998033793A1 (fr) | DERIVES DE α-AZACYCLOMETHYL BENZOTHIOPHENE ET DE α-AZACYCLOMETHYL BENZOFURANE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
FR2792316A1 (fr) | Derives de 1-aminoethylindole, leur preparation et leur application en therapeutique | |
FR2761989A1 (fr) | Derives de alpha-azacyclomethyl benzothiophene, leur preparation et leur application en therapeutique | |
FR2792313A1 (fr) | Derives de 2-aminoethyl-indole, leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09125947 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997908303 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997908303 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWR | Wipo information: refused in national office |
Ref document number: 1997908303 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997908303 Country of ref document: EP |